Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nesrin Mogulkoc

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Journal of Research in Medical Sciences : the Official Journal of Isfahan University of Medical Sciences|August 1, 2013
Pulmonary arterial hypertension and pregnancyDemet Terek, Meral Kayikcioglu, Hakan Kultursay, et al.
Respiratory Research|May 27, 2022
Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry studyDragana M Jovanovic, Martina Šterclová, Nesrin Mogulkoc, et al.
Royal Society Open Science|August 14, 2025
Tube2FEM: a general-purpose highly automated pipeline for flow-related processes in (embedded) tubular objectsHani Cheikh Sleiman, Kevin M Moerman, Diana C De Oliveira, et al.
Drug Safety|August 1, 2020
Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIREAbigél M Kolonics-Farkas, Martina Šterclová, Nesrin Mogulkoc, et al.
The Lancet. Respiratory Medicine|July 1, 2017
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?Kerri A Johannson, Irina Strâmbu, Claudia Ravaglia, et al.
Respiratory Medicine|August 27, 2020
The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosisSteven D Nathan, A Whitney Brown, Nesrin Mogulkoc, et al.
The Open Respiratory Medicine Journal|October 22, 2020
Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary FibrosisLisa Lancaster, Jonathan Goldin, Matthias Trampisch, et al.
Annals of Medicine|March 19, 2026
Statin use and its implications on survival and disease progression in the European MultiPartner idiopathic pulmonary fibrosis registry (EMPIRE)David Lang, Bernd Lamprecht, Nesrin Mogulkoc, et al.
Journal of Thoracic Disease|May 25, 2026
Adverse side-effects of antifibrotic drugs in idiopathic pulmonary fibrosis-clarification of several pointsDragana Jovanovic, Nesrin Mogulkoc, Martina Sterclova, et al.
Journal of Thoracic Disease|January 12, 2026
Adverse side-effects of antifibrotic drugs and outcome of treatment in idiopathic pulmonary fibrosisDragana Jovanovic, Nesrin Mogulkoc, Martina Sterclova, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Journal of Research in Medical Sciences : the Official Journal of Isfahan University of Medical Sciences|August 1, 2013
Pulmonary arterial hypertension and pregnancyDemet Terek, Meral Kayikcioglu, Hakan Kultursay, et al.
Respiratory Research|May 27, 2022
Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry studyDragana M Jovanovic, Martina Šterclová, Nesrin Mogulkoc, et al.
Royal Society Open Science|August 14, 2025
Tube2FEM: a general-purpose highly automated pipeline for flow-related processes in (embedded) tubular objectsHani Cheikh Sleiman, Kevin M Moerman, Diana C De Oliveira, et al.
Drug Safety|August 1, 2020
Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIREAbigél M Kolonics-Farkas, Martina Šterclová, Nesrin Mogulkoc, et al.
The Lancet. Respiratory Medicine|July 1, 2017
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?Kerri A Johannson, Irina Strâmbu, Claudia Ravaglia, et al.
Respiratory Medicine|August 27, 2020
The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosisSteven D Nathan, A Whitney Brown, Nesrin Mogulkoc, et al.
The Open Respiratory Medicine Journal|October 22, 2020
Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary FibrosisLisa Lancaster, Jonathan Goldin, Matthias Trampisch, et al.
Annals of Medicine|March 19, 2026
Statin use and its implications on survival and disease progression in the European MultiPartner idiopathic pulmonary fibrosis registry (EMPIRE)David Lang, Bernd Lamprecht, Nesrin Mogulkoc, et al.
Journal of Thoracic Disease|May 25, 2026
Adverse side-effects of antifibrotic drugs in idiopathic pulmonary fibrosis-clarification of several pointsDragana Jovanovic, Nesrin Mogulkoc, Martina Sterclova, et al.
Journal of Thoracic Disease|January 12, 2026
Adverse side-effects of antifibrotic drugs and outcome of treatment in idiopathic pulmonary fibrosisDragana Jovanovic, Nesrin Mogulkoc, Martina Sterclova, et al.
Pageof 6